产品描述 概述Recombinant Human Erythropoietin is produced by our Mammalian expression system and the target gene encoding Ala28-Arg193 is expressed with a 6His tag at the C-terminus. 使用说明This material is offered by Novin Biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. 技术规格| Tag | C-6His | | 种属 | Human | | 表达系统 | Human Cells | | Accession# | P01588 | | Source | Human Cells | | Formulation_Description | Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. | | Storage | Lyophilized protein should be stored at < -20°C, thoμgh stable at room temperature for 3 weeks.Reconstituted protein solution can be stored at 4-7°C for 2-7 days.Aliquots of reconstituted samples are stable at < -20°C for 3 months. | | Reconstitution | Dissolve the lyophilized protein in distilled water. | | Purity | Greater than 95% as determined by reducing SDS-PAGE. | | Endotoxin | Less than 0.1 ng/μg (1 EU/μg) as determined by LAL test. | | Background | Erythropoietin (EPO) is a glycoprotein hormone that is principally known for its role in erythropoiesis, where it is responsible for stimulating proliferation and differentiation of erythroid progenitor cells. Erythropoietin is a member of the EPO/TPO family. It is a secreted, glycosylated cytokine composed of four alpha helical bundles. The differentiation of CFU-E (Colony Forming Unit-Erythroid) cells into erythrocytes can only be accomplished in the presence of EPO. Physiological levels of EPO in adult mammals are maintained primarily by the kidneys, whereas levels in fetal or neonatal mammals are maintained by the liver. EPO also can exert various non-hematopoietic activities, including vascularization and proliferation of smooth muscle, neural protection during hypoxia, and stimulation of certain B cells. Genetic variation in erythropoietin is associated with susceptbility to microvascular complications of diabetes type 2. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. | | Biological_Activity | Measured in a cell proliferation assay using TF 1 human erythroleukemic cells. The ED50 for this effect is 80-250 pg/ml. |
|
